Literature DB >> 19221476

The actin-binding and bundling protein, EPLIN, is required for cytokinesis.

Megan Chircop1, Vanessa Oakes, Mark E Graham, Maggie P C Ma, Charlotte M Smith, Phillip J Robinson, Kum Kum Khanna.   

Abstract

Cytokinesis involves two phases: (1) membrane ingression followed by (2) membrane abscission. The ingression phase generates a cleavage furrow and this requires co-operative function of the actin-myosin II contractile ring and septin filaments. We demonstrate that the actin-binding protein, EPLIN, locates to the cleavage furrow during cytokinesis and this is possibly via association with the contractile ring components, myosin II and the septin, Sept2. Depletion of EPLIN results in formation of multinucleated cells and this is associated with inefficient accumulation of active myosin II (MRLC(S19)) and Sept2 and their regulatory small GTPases, RhoA and Cdc42, respectively, to the cleavage furrow during the final stages of cytokinesis. We suggest that EPLIN may function during cytokinesis to maintain local accumulation of key cytokinesis proteins at the furrow.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19221476     DOI: 10.4161/cc.8.5.7878

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  16 in total

1.  Arv1 promotes cell division by recruiting IQGAP1 and myosin to the cleavage furrow.

Authors:  Hilde Sundvold; Vibeke Sundvold-Gjerstad; Helle Malerød-Fjeld; Kaisa Haglund; Harald Stenmark; Lene Malerød
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

2.  IQGAP1 is associated with nuclear envelope reformation and completion of abscission.

Authors:  Audrey T Y Lian; Peter G Hains; Boris Sarcevic; Phillip J Robinson; Megan Chircop
Journal:  Cell Cycle       Date:  2015-04-30       Impact factor: 4.534

3.  Epithelial protein lost in neoplasm (EPLIN) interacts with α-catenin and actin filaments in endothelial cells and stabilizes vascular capillary network in vitro.

Authors:  Adeline Chervin-Pétinot; Marie Courçon; Sébastien Almagro; Alice Nicolas; Alexei Grichine; Didier Grunwald; Marie-Hélène Prandini; Philippe Huber; Danielle Gulino-Debrac
Journal:  J Biol Chem       Date:  2011-12-22       Impact factor: 5.157

4.  Estrogen induced breast cancer is the result in the disruption of the asymmetric cell division of the stem cell.

Authors:  Jose Russo; Kara Snider; Julia S Pereira; Irma H Russo
Journal:  Horm Mol Biol Clin Investig       Date:  2010-01-01

5.  Novel interactors and a role for supervillin in early cytokinesis.

Authors:  Tara C Smith; Zhiyou Fang; Elizabeth J Luna
Journal:  Cytoskeleton (Hoboken)       Date:  2010-06

6.  The diversification of the LIM superclass at the base of the metazoa increased subcellular complexity and promoted multicellular specialization.

Authors:  Bernard J Koch; Joseph F Ryan; Andreas D Baxevanis
Journal:  PLoS One       Date:  2012-03-15       Impact factor: 3.240

Review 7.  Dividing the spoils of growth and the cell cycle: The fission yeast as a model for the study of cytokinesis.

Authors:  Anupama Goyal; Masak Takaine; Viesturs Simanis; Kentaro Nakano
Journal:  Cytoskeleton (Hoboken)       Date:  2011-02

8.  Dynamin inhibitors induce caspase-mediated apoptosis following cytokinesis failure in human cancer cells and this is blocked by Bcl-2 overexpression.

Authors:  Sanket Joshi; Antony W Braithwaite; Phillip J Robinson; Megan Chircop
Journal:  Mol Cancer       Date:  2011-06-28       Impact factor: 27.401

9.  UNC119a bridges the transmission of Fyn signals to Rab11, leading to the completion of cytokinesis.

Authors:  YuKyung Lee; Sunglan Chung; In Keol Baek; Tae H Lee; Soon-Yong Paik; JooHun Lee
Journal:  Cell Cycle       Date:  2013-03-27       Impact factor: 4.534

10.  Inhibition of clathrin by pitstop 2 activates the spindle assembly checkpoint and induces cell death in dividing HeLa cancer cells.

Authors:  Charlotte M Smith; Volker Haucke; Adam McCluskey; Phillip J Robinson; Megan Chircop
Journal:  Mol Cancer       Date:  2013-01-17       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.